Artificial intelligence (AI) is an area of computer science that makes it possible for ‘machines’ to learn from new experiences and perform human-like tasks.

These AI systems are fed huge amounts of data, which they then use to learn how to carry out a specific task. The quality and size of this dataset are important for building a system able to carry out its designated task accurately.

The COVID-19 pandemic has created a sense of urgency to implement AI in dermatology. Despite this rapidly advancing field and the commercial drive to integrate AI algorithms into clinical practice as soon as possible, the current evidence-base for effectiveness of AI interventions in dermatology is weak. It does not improve patient care by enhancing the patient experience without compromising safety.

The BAD believes that AI has the potential to improve clinical care in dermatology within appropriately regulated and governed use. The public must also have confidence that AI (and the health data which fuels the development of new algorithms) is being used safely, legally and ethically.  Patient pathways in dermatology are complex and to robustly evaluate AI interventions requires clinically led research studies.

Many skin smartphone apps claim that they can classify, monitor, and treat a range of skin disorders but most have not been appropriately investigated in a recognised study setting for the interventions use in skin cancer populations.

The BAD AI Working Party Group has developed a Vision Statement on AI Interventions to establish standards that define best practice to enhance safe clinical practice and improve outcomes for people with skin disease

The BAD has convened an AI Working Party Group of experts in AI, science and academia to produce a BAD AI position statement and work with The Medicines, and Healthcare Regulatory Agency, NHSE, NHSX and AHSNs to raise awareness on the need for appropriate AI development in dermatology.

AI and Digital Regulations Service

The AI and Digital Regulations Service is a collaboration between the four organisations involved in regulating these technologies and ensuring they deliver value for money:

• The National Institute for Health and Care Excellence (NICE)
• The Medicines and Healthcare products Regulatory Agency (MHRA)
• The Health Research Authority (HRA)
• The Care Quality Commission (CQC)

It provides innovators and health and care providers with a one-stop shop for support, information and guidance on the regulation and evaluation of AI technologies.  The service provides guidance across the regulatory, evaluation and data governance pathways. This will bring benefits to the entire health and social care landscape through safer and more effective use of technology, further information can be found on their website.